- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
Nearly a quarter of the world’s new HCV infections occur among people who inject drugs (PWID): lack of access to sterile needles, syringes and other injection equipment renders them highly vulnerable to HCV. Legal and structural barriers also greatly increase HCV risk among PWID. Worldwide, more than 50% of the 15.6 million PWID are HCV antibody positive. Without urgent, strategic and measurable action that includes PWID, HCV will continue to inflict a staggering, and increasing, burden of preventable illness and death among families, communities and countries.
Sex workers experienced stock-outs of antiretroviral drugs for HIV in more than half of the countries that responded to the consultation, in all types of health care settings. Sex workers experience forced treatment interruptions and involuntary medication changes due to stock-outs, and are forced to travel long distances to access commodities and treatments due to stock-outs in their local areas. This ultimately leads to a lack of trust in health services and systems.
The consultation was convened in Malaysia (Putrajaya, 27 to 28 February 2018) by the Malaysian Ministry of Health and WHO to discuss potential approaches for validation of mother-to-child transmission of hepatitis B inviting national and international experts.
Every child should be given the best chance to start life healthy and free from preventable diseases. Mother-to-Child transmission to HIV, hepatitis B and syphilis can be effectively prevented by immunization, and screening and treatment of pregnant woman.
The Regional Framework for the Triple Elimination of Mother-to-Child Transmission of HIV, Hepatitis B and Syphilis in Asia and the Pacific 2018-2030 suggests a coordinated approach to delivering these interventions using the shared maternal, newborn and child health platform to achieve elimination.
The aim of the report is to document participation efforts and outcomes across countries, and highlight differences and constraints identified to date. In this first GLASS report data vary considerably in terms of completeness, so no attempt was made to compare AMR status at a regional or global level. However, as GLASS and country participation evolves, the data reported will help understand surveillance capacities and mechanisms of reporting across countries in all regions, and will inform further GLASS development.
AVAC's 2018 annual state of the field report, No Prevention, No End! looks at today's prevention crisis and offers context, analysis and strategy to turn that crisis around.
Keywords: HIV, PrEP, treatment, vaccine, prevention
This report summarizes the progress in implementing the Global Action Plan achieved during the first year (2017 to 2018) and the remaining challenges, with specific focus on 45 countries accounting for more than 85% of the total burden of HIV infection.
Keywords: HIVDR, prevention, response, surveillance, monitoring
This document has been designed to provide a framework to support local and national STI prevalence studies. The aim of these studies is to understand the burden of disease of Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT), two priority STIs that can cause adverse birth outcomes. For this, the objective is to epidemiologically describe the prevalence of these two infections among pregnant women and, by proxy, the general population in the country.
This report presents 2015 data on the consumption of systemic antibiotics from 65 countries and areas, contributing to our understanding of how antibiotics are used in these countries. In addition, the report documents early efforts of the World Health Organization (WHO) and participating countries to monitor antimicrobial consumption, describes the WHO global methodology for data collection, and highlights the challenges and future steps in monitoring antimicrobial consumption.
This is the first time this regimen will be offered as an affordable, generic, fixed-dose combination, which will increase access for millions of people living with HIV in low- and middle-income countries. Below are a set of key messages and questions and answers to guide communications around the announcement and respond to media inquiries.
Keywords: HIV, ART, treatment, medicines, funding